The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Open accessAbstract
Purpose: RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cSCCs). The potential of these agents to promote secondary malignancies is concerning. We analyzed cSCC and KA lesions for genetic mutations in an attempt to identify an underlying mechanism for their formation. Methods: Four international centers contributed 237 KA or cSCC tumor samples from patients receiving an RAF inhibitor (either vemurafenib or sorafenib; n = 19) or immunosuppression therapy (n = 53) or tumors that developed spontaneously (n = 165). Each sample was profiled for 396 known somatic mutations across 33 cancer-related genes by using a mass spectrometric–based genotyping platform. Results: Mutations were detected in 16% of tumors (38 of 237), with five tumors harboring two mutations. Mutations in TP53, CDKN2A, HRAS, KRAS, and PIK3CA were previously described in squamous cell tumors. Mutations in MYC, FGFR3, and VHL were identified for the first time. A higher frequency of activating RAS mutations was found in tumors from patients treated with an RAF inhibitor versus populations treated with a non–RAF inhibitor (21.1% v 3.2%; P < .01), although overall mutation rates between treatment groups were similar (RAF inhibitor, 21.1%; immunosuppression, 18.9%; and spontaneous, 17.6%; P = not significant). Tumor histology (KA v cSCC), tumor site (head and neck v other), patient age (≤ 70 v > 70 years), and sex had no significant impact on mutation rate or type. Conclusion: Squamous cell tumors from patients treated with an RAF inhibitor have a distinct mutational profile that supports a mechanism of therapy-induced tumorigenesis in RAS-primed cells. Conceivably, cotargeting of MEK together with RAF may reduce or prevent formation of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationGenetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citationVillanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Self-citationHigh-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
Self-citationCutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 554
Self-citationHauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7636 · Cited by 548
Self-citationProfiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 438
Self-citationLöhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B., & Lüttges, J. (2005) · Neoplasia · doi:10.1593/neo.04445 · Cited by 343
Non-melanoma skin cancer: what drives tumor development and progression?
Boukamp, P. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi123 · Cited by 338
Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., McCusker, J. P., Kluger, Y., & Sznol, M. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00685.x · Cited by 326
Kefford, R., Arkenau, H., Brown, M. P., Millward, M., Infante, J. R., Long, G. V., Ouellet, D., Curtis, M., Lebowitz, P. F., & Falchook, G. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8503 · Cited by 275
Platz, A., Egyhazi, S., Ringborg, U., & Hansson, J. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2007.12.003 · Cited by 260
Walker, E. M., Rodriguez, A. I., Kohn, B., Ball, R. M., Pegg, J., Pocock, J. R., Nunez, R., Peterson, E., Jakary, S., & Levine, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5150 · Cited by 228
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
Arnault, J. P., Wechsler, J., Escudier, B., Spatz, A., Tomasic, G., Sibaud, V., Aractingi, S., Grange, J.-D., Poirier-Colame, V., Malka, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4823 · Cited by 169
Self-citationGatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Whittaker, S. R., Kirk, R., Hayward, R., Zambon, A., Virós, A., Cantariño, N., Affolter, A., Nourry, A., Niculescu‐Duvaz, D., Springer, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000758 · Cited by 158
SPENCER, J. M. (1995) · Archives of Dermatology · doi:10.1001/archderm.1995.01690190048009 · Cited by 137
Ribas, A., Kim, K. B., Schuchter, L. M., González, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Flaherty, K. T., Moschos, S. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8509 · Cited by 130
Self-citationInfante, J. R., Falchook, G. S., Lawrence, D. P., Weber, J. S., Kefford, R. F., Bendell, J. C., Kurzrock, R., Shapiro, G. I., Kudchadkar, R. R., Long, G. V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.cra8503 · Cited by 122
RAF inhibition and induction of cutaneous squamous cell carcinoma
Robert, C., Arnault, J., & Mateus, C. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283436e8c · Cited by 119
Self-citationCutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
Dubauskas, Z., Kunishige, J. H., Prieto, V. G., Jonasch, E. W., Hwu, P., & Tannir, N. M. (2009) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2009.n.003 · Cited by 115
Corominas, M., Kamino, H., León, J., & Pellicer, À. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6372 · Cited by 95
Keratoacanthoma: Facts and controversies
Ko, C. J. (2010) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2009.06.010 · Cited by 91
Yakubovskaya, M. S., Spiegelman, V. S., Luo, F., Sg, M., Salnev, A., Zborovskaya, I. B., Gasparyan, A., Polotsky, B. E., Мачаладзе, З. О., Ac, T., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630611 · Cited by 83
PTCH Mutations in Squamous Cell Carcinoma of the Skin
Ping, X. L., Ratner, D., Zhang, H., Wu, X. L., Zhang, M. J., Chen, F. F., Silvers, D. N., Peacocke, M., & Tsou, H. C. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01301.x · Cited by 77
Codon 12 Harvey-ras mutations are rare events in non-melanoma human skin cancer
CAMPBELL, C., Quinn, A., & Rees, J. L. (1993) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1993.tb15137.x · Cited by 63
The histologic spectrum of epithelial neoplasms induced by sorafenib
Kwon, E. J., Kish, L. S., & Jaworsky, C. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.10.043 · Cited by 55
Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers
Zaravinos, A., Kanellou, P., & Spandidos, D. A. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09480.x · Cited by 52
Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers
Pacifico, A., Goldberg, L. H., Peris, K., Chimenti, M. S., Leone, G., & Ananthaswamy, H. N. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08360.x · Cited by 50
Sorafenib‐induced premalignant and malignant skin lesions
Williams, V. L., Cohen, P. R., & Stewart, D. J. (2011) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04822.x · Cited by 36
Actinic keratosis: Facts and controversies
Ko, C. J. (2010) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2009.06.009 · Cited by 34
Low prevalence of p53, p16INK4aand Ha-ras tumour-specific mutations in low-graded actinic keratosis
Nindl, I., Gottschling, M., Krawtchenko, N., Lehmann, M., Röwert‐Huber, J., Eberle, J., Stockfleth, E., & Forschner, T. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07857.x · Cited by 24
Lacouture, M. E., McArthur, G. A., Chapman, P. B., Ribas, A., Flaherty, K. T., Lee, R. J., Nolop, K. B., Kim, K. B., Duvic, M. A., Sosman, J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8592 · Cited by 13
Self-citationTaguchi, M., Tsuchida, T., Ikeda, S., & Sekiya, T. (1998) · Pathology International · doi:10.1111/j.1440-1827.1998.tb03969.x · Cited by 8
Cited by
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationCombined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Self-citationDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Self-citationERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Metadata
- Authors
- Oberholzer, P. A., Kee, D., Dziunycz, P., Sucker, A., Kamsukom, N., Jones, R., Roden, C., Chalk, C. J., Ardlie, K., Palescandolo, E., Piris, A., MacConaill, L. E., Robert, C., Hofbauer, G. F. L., McArthur, G. A., Schadendorf, D., & Garraway, L. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-01-20
- Volume
- 30
- Issue
- 3
- Pages
- 316-321
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2023046293
- Cited by
- 386
- References
- 42
- FWCI
- 38.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.